Castle Biosciences, Inc.最新预测显示，公司2025年总营收有望突破3.4亿美元大关，显著高于此前公布的3.27亿至3.35亿美元业绩指引上限。这一乐观预期反映出公司核心诊断业务增长动能强劲，市场对其专有基因检测服务的需求持续攀升。随着精准医疗领域加速发展，该企业通过扩大临床验证范围和优化商业布局，正不断巩固其在皮肤癌分子诊断领域的领先地位。
Castle Biosciences, Inc.最新预测显示，公司2025年总营收有望突破3.4亿美元大关，显著高于此前公布的3.27亿至3.35亿美元业绩指引上限。这一乐观预期反映出公司核心诊断业务增长动能强劲，市场对其专有基因检测服务的需求持续攀升。随着精准医疗领域加速发展，该企业通过扩大临床验证范围和优化商业布局，正不断巩固其在皮肤癌分子诊断领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.